Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Drug Royalty Corporation (DRI-TSE) -- Ignore unavailable to you. Want to Upgrade?

To: BioInv who wrote (85)	5/6/1999 9:03:00 PM
From: Drapeau	Read Replies (1) \| Respond to of 96

Bullish article in Journal Affaire$ May 1999 Translation from French article Drug Royalty: major investment by the end of August Drug Royalty prepares to acquire again part of the intellectual property of a popular drug not yet identified publicly. If its stock reacts well to this investment, Drug Royalty could ask the public for a new emission. Ezra Lwowski of Yorton Valeurs Mobilières thinks that at $2.95, the emission would not underestimate the current state of the company's position. Mr Lwowski calculates that the company will have $0.35 by shares of autogenerated funds by 2000. A multiple of 10 times the autogenerated funds seems reasonable, which places the target at $3.50. DRI has a cash position of 16 millions and a bank credit margin of 10 millions without any debt. -- Drapeau